MIKR is up about 40% to around $14 as I write this and looks like this may be the week it gets into the top 20.
My new pick in addition to MIKR for those who like to play the IBD 100 game is Bodisen Biotech (NASDAQ:BBC), which trades around $13.6 as I write this. The company engages in the development, manufacture, and sale of pesticides and compound organic fertilizers in China. This may sound boring, but it is a $17 billion market in China alone.
BBC has an IBD EPS rating of 99 (the highest possible) and its Relative Strength would also be in the 90s if it reaches $15. This would probably land BBC in a top 10 spot in the IBD 100.
Besides the IBD play, the stock could be considered a growth and value play as the company had year-over-year revenue growth of 124% and net income growth of 200% for Q1 2006. Yet, the stock trades at a P/E of only 14x the analyst estimate I found.
Additionally, the company just announced a $45 million contract last week. To put this in perspective, this new contract of $45 million is more than BBC's last four quarters of revenue combined. Any way you slice it, BBC is an interesting idea in my opinion.
Full Disclosure: The author is long BBC